Rhoen Klinikum AG (RHK) News

Alkane Resources Ltd managing director Nic Earner talked with Proactive about recent high-grade gold intercepts and ongoing resource expansion at the Tomingley gold operations in New South Wales. Earner detailed strong results from underground drilling at both the Caloma and Roswell zones, with intercepts showing multiple grams per tonne over substantial widths. “We’ve had some very, very high-grade hits… tens of metres at plus ten grams in Roswell,” he noted, highlighting the significant contribution these results will make to near-term reserve updates and future production planning. The company is confident these results will support mine life extensions well into the 2030s. Reserve and resource updates, including for Caloma One and Caloma Two, are expected in the August–September period, following analysis of the June 30 data. Earner also touched on Alkane’s recent financial performance, stating: “It’s been a great quarter… we had a great cash build,” helped by strong production and a high Australian-dollar gold price. He confirmed guidance remains on track, with 17,500 ounces produced and expectations of reaching 19,000 ounces by quarter end. Alkane continues to advance permitting for the highway relocation and is actively progressing exploration across both the Boda-Kaiser project and Tomingley region. The company is also evaluating organic growth and potential collaboration opportunities. Visit Proactive’s YouTube channel for more investor interviews. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #AlkaneResources #GoldMining #Tomingley #GoldExploration #MiningNews #ASX #OTCMarkets #GoldDrilling #ResourceUpdate #CashFlow #GoldInvesting #RoswellDrilling

European Green Transition PLC (AIM:EGT) founder and non-executive chairman Cathal Friel talked with Proactive's Stephen Gunnion about his formal move into the non-executive chairman role and the company’s strategy going forward. Friel shared how European Green Transition (EGT) aims to build value by acquiring distressed yet revenue-generating assets, a model he has successfully applied with previous companies such as Amryt Pharma and hVIVO. “Our model going forward is to acquire low-priced, distressed, good value assets, bolt them together,” he said, emphasising the need for revenue-generating components or the capacity to make acquisitions profitable from day one. He reflected on EGT’s IPO in April 2024 and his transition from other responsibilities, including his long tenure with hVIVO. With that chapter closed, he now brings more focus to EGT’s growth. Friel confirmed that the company still holds the majority of the £6.5 million raised, having only used a small portion on its rare earth asset in Sweden. Monetising that asset remains a priority. EGT's strategy continues to centre on small teams, tight cost control, and targeting multi-fold returns over a 24-month horizon. “I’ll be very careful of [the shareholders’] cash. It’s like mine,” Friel added. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #CathalFriel #EuropeanGreenTransition #EGT #RareEarths #MergersAndAcquisitions #SmallCapInvesting #GreenEconomy #MiningInvestment #ShareholderValue #hVIVO #AmrytPharma #IPO

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new development program targeting eye health. The initiative focuses on using a patented variant of the SIRT6 gene in combination with mRNA therapies. Leire explained that gene therapy is particularly well-suited for the eye due to its closed compartment, reducing the risks of off-target effects and immune responses. The company is developing two parallel therapeutic applications: one for the posterior part of the eye to address glaucoma, and another for the anterior part, targeting corneal endothelial cell preservation in transplant procedures. “We expect by a simple in vitro… to add our SIRT6 to these preservation media and help to increase the rate of positive transplantation of cornea,” said Leire, highlighting the opportunity to improve corneal transplant success rates without clinical trials. Glaucoma therapy, on the other hand, involves a more complex delivery using mRNA injections, aiming to both reduce intraocular pressure and regenerate damaged ganglion cells. The company has already signed an MTA with an ophthalmology partner to initiate early development, starting with corneal preservation and expanding into glaucoma. Genflow sees this as a fast-track opportunity to build an ophthalmology franchise with meaningful market potential and low incremental cost. For more biotech updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest insights. #GenflowBiosciences #GeneTherapy #EyeHealth #SIRT6 #GlaucomaTreatment #CorneaPreservation #BiotechNews #mRNAtherapies #Ophthalmology #CentenarianGene

Ananda Pharma Plc finance director Jeremy Sturgess-Smith talked with Proactive's Stephen Gunnion about the appointment of Chris Tovey as a strategic advisor. Tovey brings significant experience from his time as chief operating officer at GW Pharmaceuticals and later Jazz Pharmaceuticals. According to Sturgess-Smith: “He’s going to bring all that experience to Ananda,” helping guide the company through its regulatory path and corporate development. Sturgess-Smith also touched on Ananda securing ethics approval to begin its first human trial of MRX1, a key milestone for the company’s therapeutic pipeline. He noted this was the first ethics approval of its kind for any Ananda trial, with recruitment expected to begin shortly in Australia. “It’s very, very exciting to have that ethics approval in the bag,” he said. Looking ahead, the company also expects ethics approvals for studies into chemotherapy-induced peripheral neuropathy and endometriosis in the next six months. For more interviews and updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay informed.** #AnandaPharma #MRX1Trial #ClinicalTrials #CannabinoidMedicine #BiotechNews #PharmaceuticalInnovation #EthicsApproval #GWPharma #DrugDevelopment #Epidiolex #HealthInnovation #ProactiveInvestors